The US biopharmaceutical company Grace Therapeutics Inc. recently disclosed that its core candidate drug, GTX-104, is under regulatory scrutiny involving several key issues.

According to public information, the projects highlighted by regulators include research data on drug extractables, toxicological safety assessment reports, and deficiencies in the production process. Extractables data is directly related to the compatibility between drug packaging materials and formulations, serving as a key indicator for ensuring drug safety. Toxicological assessments are used to evaluate potential toxicity risks, and the integrity of both sets of data is crucial for drug approval. In addition, production deficiencies may affect the consistency and stability of drug quality. This round of regulatory attention is focused on the company's flagship product GTX-104, which is currently in a critical stage of development. Industry analysts point out that if these issues are not resolved in a timely manner, they could affect the drug’s review progress and final market launch schedule.